sur FSD Pharma Inc.
FSD Pharma Expands Research into Weight Loss and Liver Health Formulations
TORONTO, ON / ACCESSWIRE / April 17, 2024 – FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A), announced today the expansion of its research pipeline to include investigations into potential weight loss and liver health benefits through new dietary supplements and ingredient combinations. This initiative aims to address metabolic disorders and related health issues.
The company is exploring ingredients that could improve liver function, reduce metabolic disease, and decrease visceral fat. Such developments might promote liver health and weight loss. This investigation is part of FSD Pharma's strategy to broaden its product offerings, including the already in-development unbuzzd™, designed to enhance alcohol metabolism and reduce the effects of alcohol intoxication.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de FSD Pharma Inc.